Wirelessly rechargeable brain implants could make it easier for researchers to control individual neurons in rats using pulses of lights. Optogenetics is a research tool in neuroscience that uses ...

While islet cell transplants allow some diabetics to forgo daily insulin injections, those people have to take immunosuppressive drugs in order to keep the cells from being rejected. A new implant, ...

Wednesday, Vivani Medical Inc (NASDAQ:VANI) released preclinical data on weight loss effects for NPM-115, the company’s miniature, twice-yearly exenatide subdermal implant under development for ...

Company to Proceed with Phase 2 Development Program for Islatravir Subdermal Implant “We are delighted to share our early data at CROI 2021 supporting the potential for a once-yearly dosing regimen ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in development ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a Phase 1 study evaluating the safety, tolerability and ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset ...

A phase 1 trial has found an implantable formulation of Merck’s islatravir could protect against HIV for at least one year. Merck is now preparing to start a phase 2 study of the subdermal implant. A ...

The novel, subdermal implant, developed by scientists from the Oak Crest Institute of Science, provides sustained release of potent antiretroviral drugs which are showing extreme promise in preventing ...